Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas

SIMPLE SUMMARY: After initially responding to empiric radio-chemotherapy, most advanced thymomas and thymic carcinomas become refractory and require second-line therapies. The multi-target tyrosine kinase inhibitor, sunitinib, is one of few options, especially in patients with thymic carcinomas, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Küffer, Stefan, Grabowski, Jessica, Okada, Satoru, Sojka, Nikolai, Welter, Stefan, von Hammerstein-Equord, Alexander, Hinterthaner, Marc, Cordes, Lucia, von Hahn, Xenia, Müller, Denise, Sauer, Christian, Bohnenberger, Hanibal, Marx, Alexander, Ströbel, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562918/
https://www.ncbi.nlm.nih.gov/pubmed/36230684
http://dx.doi.org/10.3390/cancers14194762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562918/
https://www.ncbi.nlm.nih.gov/pubmed/36230684
http://dx.doi.org/10.3390/cancers14194762

Ejemplares similares